![Rob R. Ruijtenbeek](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Rob R. Ruijtenbeek
Corporate Officer/Principal bei PamGene International BV
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Patrick van Beneden | M | 62 |
PamGene International BV
![]() PamGene International BV Pharmaceuticals: MajorHealth Technology PamGene is a biomarker company, focused on opening up new opportunities for the development of Personalized Medicine (pre-clinical, translational and clinical). Most of PamGene's projects are in oncology and many of these involve medicines that inhibit or modulate cellular kinases and kinase pathways. The firm collaborators apply its technologies for biomarker research in several other diseases and fields of expertise such as the Central Nervous System, the Cardiovascular area, Immunology and Obesity. PamGene's technology offers a faster and lower risk route for discovery and development of clinically useful biomarkers and uses cell lines and retrospective patient sample collection testing. | 24 Jahre |
Tim Kievits | M | - |
PamGene International BV
![]() PamGene International BV Pharmaceuticals: MajorHealth Technology PamGene is a biomarker company, focused on opening up new opportunities for the development of Personalized Medicine (pre-clinical, translational and clinical). Most of PamGene's projects are in oncology and many of these involve medicines that inhibit or modulate cellular kinases and kinase pathways. The firm collaborators apply its technologies for biomarker research in several other diseases and fields of expertise such as the Central Nervous System, the Cardiovascular area, Immunology and Obesity. PamGene's technology offers a faster and lower risk route for discovery and development of clinically useful biomarkers and uses cell lines and retrospective patient sample collection testing. | 25 Jahre |
Theo van der Leij | M | - |
PamGene International BV
![]() PamGene International BV Pharmaceuticals: MajorHealth Technology PamGene is a biomarker company, focused on opening up new opportunities for the development of Personalized Medicine (pre-clinical, translational and clinical). Most of PamGene's projects are in oncology and many of these involve medicines that inhibit or modulate cellular kinases and kinase pathways. The firm collaborators apply its technologies for biomarker research in several other diseases and fields of expertise such as the Central Nervous System, the Cardiovascular area, Immunology and Obesity. PamGene's technology offers a faster and lower risk route for discovery and development of clinically useful biomarkers and uses cell lines and retrospective patient sample collection testing. | - |
Mark Wegter | M | 54 |
PamGene International BV
![]() PamGene International BV Pharmaceuticals: MajorHealth Technology PamGene is a biomarker company, focused on opening up new opportunities for the development of Personalized Medicine (pre-clinical, translational and clinical). Most of PamGene's projects are in oncology and many of these involve medicines that inhibit or modulate cellular kinases and kinase pathways. The firm collaborators apply its technologies for biomarker research in several other diseases and fields of expertise such as the Central Nervous System, the Cardiovascular area, Immunology and Obesity. PamGene's technology offers a faster and lower risk route for discovery and development of clinically useful biomarkers and uses cell lines and retrospective patient sample collection testing. | 24 Jahre |
Rinie van Beuningen | M | - |
PamGene International BV
![]() PamGene International BV Pharmaceuticals: MajorHealth Technology PamGene is a biomarker company, focused on opening up new opportunities for the development of Personalized Medicine (pre-clinical, translational and clinical). Most of PamGene's projects are in oncology and many of these involve medicines that inhibit or modulate cellular kinases and kinase pathways. The firm collaborators apply its technologies for biomarker research in several other diseases and fields of expertise such as the Central Nervous System, the Cardiovascular area, Immunology and Obesity. PamGene's technology offers a faster and lower risk route for discovery and development of clinically useful biomarkers and uses cell lines and retrospective patient sample collection testing. | 23 Jahre |
Martine Hulselmans | F | - |
PamGene International BV
![]() PamGene International BV Pharmaceuticals: MajorHealth Technology PamGene is a biomarker company, focused on opening up new opportunities for the development of Personalized Medicine (pre-clinical, translational and clinical). Most of PamGene's projects are in oncology and many of these involve medicines that inhibit or modulate cellular kinases and kinase pathways. The firm collaborators apply its technologies for biomarker research in several other diseases and fields of expertise such as the Central Nervous System, the Cardiovascular area, Immunology and Obesity. PamGene's technology offers a faster and lower risk route for discovery and development of clinically useful biomarkers and uses cell lines and retrospective patient sample collection testing. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Bas Xue | M | - |
University of Utrecht
| 6 Jahre |
Mehmet Bulut | M | 54 |
University of Utrecht
| 3 Jahre |
Eveline Speelman | M | - |
University of Utrecht
| 5 Jahre |
Jean Deleage | M | 83 |
PamGene International BV
![]() PamGene International BV Pharmaceuticals: MajorHealth Technology PamGene is a biomarker company, focused on opening up new opportunities for the development of Personalized Medicine (pre-clinical, translational and clinical). Most of PamGene's projects are in oncology and many of these involve medicines that inhibit or modulate cellular kinases and kinase pathways. The firm collaborators apply its technologies for biomarker research in several other diseases and fields of expertise such as the Central Nervous System, the Cardiovascular area, Immunology and Obesity. PamGene's technology offers a faster and lower risk route for discovery and development of clinically useful biomarkers and uses cell lines and retrospective patient sample collection testing. | 11 Jahre |
Reinier de Jong | M | - |
University of Utrecht
| 3 Jahre |
David Welch | M | - |
University of Utrecht
| 4 Jahre |
Jakob Hits | M | - |
University of Utrecht
| 7 Jahre |
Rong Guo Qiu | M | 62 |
University of Utrecht
| 3 Jahre |
Robert Emile Hartog | M | - |
University of Utrecht
| 6 Jahre |
Machteld Groeneveld | F | - |
University of Utrecht
| 5 Jahre |
Herbert Schilperoord | M | - |
University of Utrecht
| 5 Jahre |
André van Puijenbroek | M | - |
University of Utrecht
| 3 Jahre |
Marnix van der Feltz | M | - |
University of Utrecht
| 6 Jahre |
Jochem Baalmann | M | - |
University of Utrecht
| 1 Jahre |
Jan Frens van Giessel | M | - |
University of Utrecht
| 5 Jahre |
Judith Bia | F | - |
University of Utrecht
| 4 Jahre |
Robert Kraal | M | 50 |
University of Utrecht
| 1 Jahre |
Michiel van Wissen | M | 41 |
University of Utrecht
| 5 Jahre |
Erik H. van Beers | M | - |
University of Utrecht
| 4 Jahre |
Alexander Ery Wibowo | M | 44 |
University of Utrecht
| 3 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Niederlande | 26 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Rob R. Ruijtenbeek
- Persönliches Netzwerk